Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc MRNA shares are trading lower by 3.15% at $131.52. Vaccine stocks are falling in sympathy with Novavax, Inc. NVAX, which reported worse-than-expected first-quarter EPS and sales results.

Novavax reported first-quarter revenue of $704 million, which came in below the $845.2 million estimate. The company reported quarterly earnings of $2.56 per share, which came in below the estimate of $2.69 per share... Read More

Moderna is a commercial-stage biotech. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine.

According to data from Benzinga Pro, Moderna has a 52-week high of $497.49 and a 52-week low of $122.01.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!